作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Carotid Body Tumor, Cardiac Paraganglioma, Adrenal Pheochromocytoma: A Contest with Hypercatecholamineemia
-
摘要: 一例老年男性患者，同时合并左颈部副神经节瘤、心脏副神经节瘤及右肾上腺嗜铬细胞瘤，病例罕见，病情复杂，诊治难度大，经2次多学科团队共同讨论，我院先后为患者切除心脏和右肾上腺病灶，术后患者顺利出院，获得了良好的治疗效果。该患者的诊治过程体现了多学科协作可在疑难重症诊疗过程中发挥重要作用。Abstract: This patient was an elderly man with left carotid body tumor, cardiac paraganglioma and right adrenal pheochromocytoma at the same time. It was a rare case with a complex condition, and the diagnosis and treatment were difficult. After two rounds of discussion in the multidisciplinary team, our hospital successively removed the lesions of the heart and the right adrenal, and the patient was discharged smoothly after the operations. The diagnosis and treatment of this patient reflects the significance of the multidisciplinary team on the diagnosis and treatment of difficult diseases.
-
Key words:
- paraganglioma /
- pheochromocytoma /
- adrenal gland /
- catecholamine
作者贡献：孙娟、刘剑州负责患者管理，案例收集及随访，文章撰写及修改；文进、李汉忠、纪志刚、董德鑫、叶子兴、苗齐、童安莉、黄宇光、隆云为MDT团队成员，负责患者的诊治及病情讨论，提供文章修改建议；文进负责文章审核及修改。利益冲突：无 -
表 1 患者心脏副神经节瘤切除术前酚苄明用量及血压、心率控制情况(2020年)
日期 酚苄明剂量及频次 血压 心率 9月17日—9月19日 5 mg，每天1次 144/98 mm Hg(卧位) - 9月20日—9月22日 5 mg，每天3次 140/90 mm Hg(卧位) - 9月23日—9月25日 10 mg，每天2次 136/72 mm Hg(卧位)，108/45 mm Hg(立位) 72次/min(卧位)，95次/min(立位) 9月26日—9月29日 10 mg，每天3次 136/70 mm Hg(卧位)，105/65 mm Hg(立位) 72次/min(卧位)，93次/min(立位) 9月30日—10月3日 20 mg，每天2次 152/77 mm Hg(卧位)，127/60 mm Hg(立位) 72次/min(卧位)，92次/min(立位) 10月4日—10月15日 20 mg，每天3次 147/75 mm Hg(卧位)，127/65 mm Hg(立位) 67次/min(卧位)，97次/min(立位) -：未测量 
下载: 导出CSV
-
[1] 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36: 737-750. [2] Beard CM, Sheps SG, Kurland LT, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979[J]. Mayo Clin Proc, 1983, 58: 802-804. http://www.ncbi.nlm.nih.gov/pubmed/6645626 [3] McNeil AR, Blok BH, Koelmeyer TD, et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland[J]. Aust N Z J Med, 2000, 30: 648-652. doi: 10.1111/j.1445-5994.2000.tb04358.x [4] Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series[J]. Mayo Clin Proc, 1981, 56: 354-360. http://europepmc.org/abstract/med/6453259 [5] Scoazec JY, Couvelard A, Réseau TENpath. Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future[J]. Ann Pathol, 2017, 37: 444-456. doi: 10.1016/j.annpat.2017.10.003 [6] Abdelhady K, Durgam S, Orza D, et al. Left Atrial and Carotid Body Paraganglioma[J]. Ann Thorac Surg, 2017, 103: e323-e325. doi: 10.1016/j.athoracsur.2016.09.062 [7] Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients[J]. J Clin Endocrinol Metab, 2001, 86: 5210-5216. doi: 10.1210/jcem.86.11.8034 [8] Al-Harthy M, Al-Harthy S, Al-Otieschan A, et al. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas[J]. Endocr Pract, 2009, 15: 194-202. doi: 10.4158/EP.15.3.194 [9] Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification[J]. Endocr Pathol, 2012, 23: 4-14. doi: 10.1007/s12022-011-9188-1 [10] Kimura N, Watanabe T, Noshiro T, et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors[J]. Endocr Pathol, 2005, 16: 23-32. doi: 10.1385/EP:16:1:023 [11] Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases[J]. Am J Surg Pathol, 2002, 26: 551-566. doi: 10.1097/00000478-200205000-00002 [12] Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis[J]. Surgery, 2008, 143: 759-768. doi: 10.1016/j.surg.2008.02.007 [13] de Wailly P, Oragano L, Radé F, et al. Malignant pheochromocytoma: new malignancy criteria[J]. Langenbecks Arch Surg, 2012, 397: 239-246. doi: 10.1007/s00423-011-0850-3 [14] Agarwal A, Mehrotra PK, Jain M, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?[J]. World J Surg, 2010, 34: 3022-3028. doi: 10.1007/s00268-010-0744-5 [15] Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer[J]. Pancreas, 2010, 39: 775-783. doi: 10.1097/MPA.0b013e3181ebb4f0 [16] Boedeker CC, Neumann HP, Offergeld C, et al. Clinical features of paraganglioma syndromes[J]. Skull Base, 2009, 19: 17-25. doi: 10.1055/s-0028-1103123 [17] Shen WT, Grogan R, Vriens M, et al. One Hundred Two Patients With Pheochromocytoma Treated at a Single Institution Since the Introduction of Laparoscopic Adrenalectomy[J]. Arch Surg, 2010, 145: 893-897. doi: 10.1001/archsurg.2010.159 [18] Huang KH, Chung SD, Chen SC, et al. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute[J]. Int J Urol, 2007, 14: 181-185. doi: 10.1111/j.1442-2042.2007.01687.x [19] Jain A, Baracco R, Kapur G. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management[J]. Pediatr Nephrol, 2020, 35: 581-594. doi: 10.1007/s00467-018-4181-2 [20] Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma[J]. Front Pediatr, 2017, 5: 155. doi: 10.3389/fped.2017.00155 -
点击查看大图
图(3) / 表(1)
计量
- 文章访问数: 451
- HTML全文浏览量: 68
- PDF下载量: 126
- 被引次数: 0
